|
 |
 |
|
Agennix
Agennix, a privately held biopharmaceutical company, is the world leader in the development of Talactoferrin Alfa, an immuno-stimulatory protein for pharmaceutical use. Talactoferrin has demonstrated efficacy in Phase 2 placebo-controlled trials in non-small cell lung cancer and diabetic foot ulcers. The company is preparing to initiate Phase 3 clinical trials in these indications.
|
|
|
 |
|
EnVivo Pharmaceuticals
EnVivo is a biopharmaceutical company dedicated to discovering and developing drugs for central nervous system (CNS) disorders, currently focusing on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and Spinocerebellar ataxias. The company’s lead programs include a Nicotinic Acetylcholine Receptor Agonist Program for Alzheimer’s disease, a Histone Deacetylase (HDAC) Program for Huntington’s disease and a Neuroprotection Program (EVPK-0003546) for Huntington’s disease as well as other neurodegenerative indications.
|
|
|
 |
|
Fairway Medical Technologies
Fairway Medical Technologies is an integrated medical device company with broad experience and expertise in the commercialization of innovative technologies as well as contract design and manufacturing services for the life science industry.
|
|
|
 |
|
Kardia Therapeutics, Inc.
Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics’ portfolio of technologies utilizes three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia’s technologies have the potential to offer significantly improved patient outcomes compared to existing treatments. For Additional Information Contact: Dr. Alfred (Buz) Brown
|
|
|
|
 |
|
Kryptiq Corporation
Kryptiq is the leading provider of workflow connectivity solutions for healthcare. Kryptiq streamlines healthcare communications among patients, providers, pharmacies and healthplans with secure messaging electronic prescribing, disease management and contract management technologies. By integrating these solutions with existing systems and applications, Kryptiq enables the trusted transport of health information where and when it is needed.
|
|
|
 |
|
Medical Metrics
Medical Metrics is a medical software and services company that provides radiographic analysis services for investigational device trials as well as clinical diagnostics for the orthopedic and related medical specialties. The company's end product Medical Metrics’ Quantiative Motion Analysis (QMAtm), is the new standard for intervertebral motion measurements and spine fusion assessment and is used by most top medical device firms in support of clinical and preclinical studies.
|
|
|
 |
|
MithraGen
MithraGen is developing innovative immunotherapies designed to optimize the functions of the immune system's T and B cells for the treatment and prevention of cancer and infectious diseases. Mithragen's product development activities are centered around the company's proprietary vaccine platform, MithraVax, a flexible vaccine technology with the potential to turn antigens into potent immunostimulants, capable of generating a complete immune response.
|
|
|
 |
|
Molecular Logix, Inc.
MLX is a drug discovery company located in The Woodlands, Texas, that seeks to discover novel therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.
|
|
|
 |
|
Oncovance Technologies
Oncovance provides information management and analytical services coupled with innovative, proprietary predictive solutions to the healthcare industry. The Company has developed a suite of technologies and products to enable Personalized Evidence-Based Medicine(TM) which streamline therapeutics development, support and promote diagnostic and therapeutic products, and improve the quality of patient care. Initial efforts are directed toward urologic cancer and benign prostate hyperplasia.
|
|
|
 |
|
Opexa Therapeutics (NASDAQ: OPXA)
Opexa Therapeutics is a publicly-traded cellular therapy company located in the Woodlands, TX (outside of Houston) with two proprietary, broad technical therapeutic platforms: T-cell vaccination and autologous stem cell therapy. Opexa Therapeutics is developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, cardiovascular disease, and diabetes.
|
|
|
 |
|
Progression Therapeutics
Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a novel tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo. For Additional Information Contact: Dr. Glenn A. Friedrich
|
|
|
 |
|
Prokaryon Technologies, Inc.
Prokaryon Technologies, Inc., is a animal health company that develops solutions for the prevention and control of economically devastating diseases in food animals. The focus of the company is the discovery, development, and commercialization of innovative veterinary products. Prokaryon's lead product is a genomics-derived vaccine to prevent shipping fever in cattle. For Additional Information Contact: Dr. John S. Swartley
|
|
|
 |
|
Relievant MedSystems
www.relievant.com
Relievant MedSystems is a medical device company developing novel products to treat lower back pain using a minimally invasive therapeutic approach. The company was founded in 2004 and is headquartered in San Francisco, California.
|
|
|
 |
|
Sapphire Therapeutics (formerly Rejuvenon)
Sapphire is a biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or pre-clinical testing in oncologic and metabolic disease. The most advanced drug candidate in Sapphire's pipeline is a small molecule ghrelin agonist that is currently in Phase II human clinical trials for cancer cachexia.
|
|
|
